Pembrolizumab Antitumor Activity in Relapsed/Refractory Classical Hodgkin Lymphoma in Keynote-087: Revised Response Criteria for Malignant Lymphoma 2007 Criteria Versus Lugano 2014 Classification

被引：0
|
作者：
Moskowitz, Craig H.
Chen, Robert W.
Armand, Philippe
Zinzani, Pier Luigi
Vassilakopoulos, Theodoros P.
Goldmacher, Gregory V.
Lin, Jianxin
Nahar, Akash
Balakumaran, Arun
Salles, Gilles
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4085
引用
收藏
页数：4
相关论文
共 36 条
  • [21] Cost-effectiveness of pembrolizumab versus brentuximab vedotin for patients with relapsed or refractory classical Hodgkin's lymphoma: a United States payer perspective
    Large, Samuel
    Hettle, Robert
    Balakumaran, Arun
    Wu, Elise
    Borse, Rebekah H.
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (01) : 16 - 25
  • [22] Efficacy and safety of pembrolizumab every six weeks in relapsed/refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma: The phase 2 KEYNOTE-B68 trial.
    McDonald, Andrew Bruce
    Verburgh, Estelle
    Gotti, Manuel
    Pinto, Antonio
    Zaucha, Jan
    Ivanov, Vladimir
    Melnichenko, Vladimir
    Mocikova, Heidi
    Ozcan, Muhit
    Patti, Caterina
    Farias, Joao
    Goncalves, Iara
    Mayer, Jiri
    Saydam, Guray
    Tomassetti, Sarah
    Pathiraja, Kumudu
    Ryland, Katherine
    Chakraborty, Samhita
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB VERSUS BRENTUXIMAB VEDOTIN (BV) IN ADULT AND PAEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA IN FRANCE
    Minacori, R.
    Apert, M.
    Leproust, S.
    Monnier, R.
    Casasnovas, R. O.
    Brice, P.
    Borse, R. H.
    Gandhi, J.
    Rai, A.
    VALUE IN HEALTH, 2022, 25 (01) : S55 - S55
  • [24] Initial results from an international study in relapsed/refractory aggressive non-Hodgkin's lymphoma to confirm the activity, safety and criteria for predicting response to lenalidomide monotherapy
    Wilzig, Thomas E.
    Reeder, Craig B.
    Polikoff, Jonathan
    Chowhan, Naveed M.
    Esseessee, Isaac
    Greenberg, Richard
    Patel, Hermant
    Vafai, Davood
    Wiernik, Peter H.
    Ervin-Haynes, Annette
    Pietronigro, Dennis
    Zeldis, Jerome B.
    Czuczman, Myron
    BLOOD, 2007, 110 (11) : 758A - 758A
  • [25] Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study (vol 22, pg 512, 2021)
    Kuruvilla, J.
    Ramchandren, R.
    Santoro, A.
    LANCET ONCOLOGY, 2021, 22 (05): : E184 - E184
  • [26] 1. INDIRECT TREATMENT COMPARISON OF PEMBROLIZUMAB VERSUS STANDARD-OF-CARE FOR RELAPSED AND REFRACTORY CLASSICAL HODGKIN'S LYMPHOMA USING TIME-VARYING HAZARD RATIOS
    Wu, E.
    Keeping, S.
    Chan, K.
    Mojebi, A.
    Balakumaran, A.
    VALUE IN HEALTH, 2018, 21 : S223 - S223
  • [27] KEYNOTE-204: Randomized, open-label, phase III study of pembrolizumab (pembro) versus brentuximab vedotin (BV) in relapsed or refractory classic Hodgkin lymphoma (R/R cHL).
    Kuruvilla, John
    Ramchandren, Radhakrishnan
    Santoro, Armando
    Paszkiewicz-Kozik, Ewa
    Gasiorowski, Robin
    Johnson, Nathalie
    Melnichenko, Vladimir
    Fogliatto, Laura Maria
    Goncalves, Iara
    de Oliveira, Jose
    Buccheri, Valeria
    Perini, Guilherme Fleury
    Goldschmidt, Neta
    Alekseev, Sergey
    Kryachok, Iryna
    Sekiguchi, Naohiro
    Zhu, Ying
    Nahar, Akash
    Marinello, Patricia
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [28] KEYNOTE B68: Open-label phase 2 study of the efficacy and safety of pembrolizumab administered every six weeks in patients with relapsed or refractory classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma.
    Armand, Philippe
    Pathiraja, Kumudu
    Chakraborty, Samhita
    Marinello, Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [29] High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma
    Moskowitz, Alison J.
    Shah, Gunjan L.
    Schoder, Heiko
    Hancock, Helen
    Davey, Theresa
    Joong, Christopher
    Pomerantz, Lauren
    Jarjies, Christine
    Kumar, Anita
    Lahoud, Oscar B.
    Batlevi, Connie Lee
    Hamlin, Paul A.
    Straus, David J.
    Rodriguez-Rivera, Ildefonso
    Owens, Colette
    Caron, Philip
    Colbourn, Donald Steven
    Intlekofer, Andrew M.
    Hamilton, Audrey
    Horwitz, Steven M.
    Joffe, Erel
    Palomba, M. Lia
    Noy, Ariela
    Matasar, Matthew J.
    Vardhana, Santosha
    von Keudell, Gottfried R.
    Yahalom, Joachim
    Younes, Anas
    Zelenetz, Andrew D.
    Moskowitz, Craig H.
    BLOOD, 2019, 134
  • [30] Comparison of interim PET response to relapse vs. first-line treatment in children with classical Hodgkin lymphoma (HL) - contribution to the development of response criteria for relapsed HL
    Kluge, R.
    Wittig, T.
    Hasenclever, D.
    Kurch, L.
    Georgi, T. W.
    Mauz-Koerholz, C.
    Koerholz, D.
    KLINISCHE PADIATRIE, 2020, 232 (02): : 111 - 111
1234